Zevra Therapeutics, Inc. Business Acquisition, Pro Forma Net Income (Loss)
Zevra Therapeutics, Inc. (ZVRA) reported Business Acquisition, Pro Forma Net Income (Loss) of -$8.21 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2024-11-13
- Zevra Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2024-06-30 was -$8.21M.
- Zevra Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2024-03-31 was -$20.65M.
- Zevra Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2023-12-31 was -$24.11M.
- Zevra Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2023-09-30 was -$25.90M.
- Zevra Therapeutics, Inc. business acquisition, pro forma net income (loss) for fiscal 2023 was -$78.88M.
- Zevra Therapeutics, Inc. business acquisition, pro forma net income (loss) for fiscal 2022 was -$80.65M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2024-06-30 | -$8.21M 10-Q · filed 2024-08-14 | -$28.86M 10-Q · filed 2024-08-14 | -$52.98M derived: sum of 3 quarters · filed 2024-08-14 | -$78.88M derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-03-31 | -$20.65M 10-Q · filed 2024-05-09 | -$44.76M derived: sum of 2 quarters · filed 2024-05-09 | -$70.66M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-12-31 | -$24.11M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$50.01M derived: sum of 2 quarters · filed 2024-11-13 | -$78.88M 10-K · filed 2024-04-01 | |
| 2023-09-30 | -$25.90M 10-Q · filed 2024-11-13 | -$54.76M 10-Q · filed 2024-11-13 | ||
| 2022-12-31 | -$80.65M 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |